Skip to main content
Download PDF
- Main
Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).
Published Web Location
https://doi.org/10.1200/jco.2016.34.15_suppl.2037Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.